The Use of Vyvanse in the Treatment of Binge Eating Disorder

Table of ContentsView AllTable of ContentsWhat Is Binge Eating Disorder?Vyvanse for BEDDosingPrecautions and Side Effects

Table of ContentsView All

View All

Table of Contents

What Is Binge Eating Disorder?

Vyvanse for BED

Dosing

Precautions and Side Effects

Vyvanse (lisdexamfetamine dimesylate) is an FDA-approved central nervous system stimulant used to treat ADHD and binge eating disorder (BED). While is not approved for weight loss, the use of Vyvanse for moderate-to-severe BED can lead to weight loss.

BED is an eating disorder that was added to theDiagnostic and Statistical Manual of Mental Disorders(DSM–5) in 2013. It involves recurring episodes of binge eating without purging and accompanying feelings of remorse afterward.

Binge eating can lead to weight gain and ultimately obesity. It is defined as eating a significantly larger than normal portion of food in a short period of time and feeling that you cannot stop or control how much you are eating.

To be diagnosed with BED, a marked level of distress regarding binge eating must be present, the binging must not be associated with purging or over-exercising to compensate, and the behavior must occur at least once a week for three months.

The Difference Between Binge Eating and Overeating

Vyvanse for Binge Eating Disorder

Individual or group therapy, including cognitive-behavioral therapy (CBT), interpersonal psychotherapy, and dialectical behavior therapy (DBT), are recommended for the treatment of BED. In addition, the U.S. Food & Drug Administration approved Vyvanse as the first drug to treat BED in 2010.

Inpreclinical trialsof patients with moderate to severe BED, Vyvanse was shown to significantly reduce the frequency of binge eating days. It was also shown to be effective at aiding in the prevention of relapse.

Understanding Binge Eating and ADHD

Vyvanse is acontrolled substance, which means it is more regulated than some other prescription drugs. In most states, you will need to see your doctor each month to obtain a new prescription. Refill requests likely cannot be made over the phone.

Since Vyvanse is a central nervous system stimulant, it comes with some risks. It is in a class of drugs known as amphetamines, which have a high potential for abuse and dependence. They are also linked to serious cardiovascular reactions, including sudden death, stroke, and heart attack. People with a known hypersensitivity to amphetamine products or those who take monoamine oxidase inhibitors (MAOIs) should not take Vyvanse.

Common side effects from Vyvanse use include:

A Word From Verywell

What Medications Are Used to Treat Binge Eating?

9 SourcesVerywell Mind uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Ghaderi A, Odeberg J, Gustafsson S, et al. Psychological, pharmacological, and combined treatments for binge eating disorder: a systematic review and meta-analysis. PeerJ. 2018;6:e5113. doi:10.7717/peerj.5113Burrows T, Skinner J, Mckenna R, Rollo M. Food Addiction, Binge Eating Disorder, and Obesity: Is There a Relationship?. Behav Sci (Basel). 2017;7(3) doi:10.3390/bs7030054Brownley KA, Berkman ND, Peat CM, et al. Binge-Eating Disorder in Adults: A Systematic Review and Meta-analysis. Ann Intern Med. 2016;165(6):409-20. doi:10.7326/M15-2455Guerdjikova AI, Mori N, Casuto LS, Mcelroy SL. Novel pharmacologic treatment in acute binge eating disorder - role of lisdexamfetamine. Neuropsychiatr Dis Treat. 2016;12:833-41. doi:10.2147/NDT.S80881De jong M, Schoorl M, Hoek HW. Enhanced cognitive behavioural therapy for patients with eating disorders: a systematic review. Curr Opin Psychiatry. 2018;31(6):436-444. doi:10.1097/YCO.0000000000000452Mcelroy SL, Hudson J, Ferreira-cornwell MC, Radewonuk J, Whitaker T, Gasior M. Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials. Neuropsychopharmacology. 2016;41(5):1251-60. doi:10.1038/npp.2015.275Hudson JI, Mcelroy SL, Ferreira-cornwell MC, Radewonuk J, Gasior M. Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2017;74(9):903-910. doi:10.1001/jamapsychiatry.2017.1889Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present–a pharmacological and clinical perspective. J Psychopharmacol (Oxford). 2013;27(6):479-96. doi:10.1177/0269881113482532Coghill DR, Caballero B, Sorooshian S, Civil R. A systematic review of the safety of lisdexamfetamine dimesylate. CNS Drugs. 2014;28(6):497-511. doi: 10.1007/s40263-014-0166-2Additional ReadingHighlights of prescribing information: Vyvance. U.S. Food and Drug Administration.Binge eating disorder. National Eating Disorders Association.Heo Y, Duggan S.Lisdexamfetamine: A review in binge eating disorder.CNS Drugs. 2017;31(11):1015-1022. doi:10.1007/s40263-017-0477-1

9 Sources

Verywell Mind uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Ghaderi A, Odeberg J, Gustafsson S, et al. Psychological, pharmacological, and combined treatments for binge eating disorder: a systematic review and meta-analysis. PeerJ. 2018;6:e5113. doi:10.7717/peerj.5113Burrows T, Skinner J, Mckenna R, Rollo M. Food Addiction, Binge Eating Disorder, and Obesity: Is There a Relationship?. Behav Sci (Basel). 2017;7(3) doi:10.3390/bs7030054Brownley KA, Berkman ND, Peat CM, et al. Binge-Eating Disorder in Adults: A Systematic Review and Meta-analysis. Ann Intern Med. 2016;165(6):409-20. doi:10.7326/M15-2455Guerdjikova AI, Mori N, Casuto LS, Mcelroy SL. Novel pharmacologic treatment in acute binge eating disorder - role of lisdexamfetamine. Neuropsychiatr Dis Treat. 2016;12:833-41. doi:10.2147/NDT.S80881De jong M, Schoorl M, Hoek HW. Enhanced cognitive behavioural therapy for patients with eating disorders: a systematic review. Curr Opin Psychiatry. 2018;31(6):436-444. doi:10.1097/YCO.0000000000000452Mcelroy SL, Hudson J, Ferreira-cornwell MC, Radewonuk J, Whitaker T, Gasior M. Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials. Neuropsychopharmacology. 2016;41(5):1251-60. doi:10.1038/npp.2015.275Hudson JI, Mcelroy SL, Ferreira-cornwell MC, Radewonuk J, Gasior M. Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2017;74(9):903-910. doi:10.1001/jamapsychiatry.2017.1889Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present–a pharmacological and clinical perspective. J Psychopharmacol (Oxford). 2013;27(6):479-96. doi:10.1177/0269881113482532Coghill DR, Caballero B, Sorooshian S, Civil R. A systematic review of the safety of lisdexamfetamine dimesylate. CNS Drugs. 2014;28(6):497-511. doi: 10.1007/s40263-014-0166-2Additional ReadingHighlights of prescribing information: Vyvance. U.S. Food and Drug Administration.Binge eating disorder. National Eating Disorders Association.Heo Y, Duggan S.Lisdexamfetamine: A review in binge eating disorder.CNS Drugs. 2017;31(11):1015-1022. doi:10.1007/s40263-017-0477-1

Ghaderi A, Odeberg J, Gustafsson S, et al. Psychological, pharmacological, and combined treatments for binge eating disorder: a systematic review and meta-analysis. PeerJ. 2018;6:e5113. doi:10.7717/peerj.5113Burrows T, Skinner J, Mckenna R, Rollo M. Food Addiction, Binge Eating Disorder, and Obesity: Is There a Relationship?. Behav Sci (Basel). 2017;7(3) doi:10.3390/bs7030054Brownley KA, Berkman ND, Peat CM, et al. Binge-Eating Disorder in Adults: A Systematic Review and Meta-analysis. Ann Intern Med. 2016;165(6):409-20. doi:10.7326/M15-2455Guerdjikova AI, Mori N, Casuto LS, Mcelroy SL. Novel pharmacologic treatment in acute binge eating disorder - role of lisdexamfetamine. Neuropsychiatr Dis Treat. 2016;12:833-41. doi:10.2147/NDT.S80881De jong M, Schoorl M, Hoek HW. Enhanced cognitive behavioural therapy for patients with eating disorders: a systematic review. Curr Opin Psychiatry. 2018;31(6):436-444. doi:10.1097/YCO.0000000000000452Mcelroy SL, Hudson J, Ferreira-cornwell MC, Radewonuk J, Whitaker T, Gasior M. Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials. Neuropsychopharmacology. 2016;41(5):1251-60. doi:10.1038/npp.2015.275Hudson JI, Mcelroy SL, Ferreira-cornwell MC, Radewonuk J, Gasior M. Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2017;74(9):903-910. doi:10.1001/jamapsychiatry.2017.1889Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present–a pharmacological and clinical perspective. J Psychopharmacol (Oxford). 2013;27(6):479-96. doi:10.1177/0269881113482532Coghill DR, Caballero B, Sorooshian S, Civil R. A systematic review of the safety of lisdexamfetamine dimesylate. CNS Drugs. 2014;28(6):497-511. doi: 10.1007/s40263-014-0166-2

Burrows T, Skinner J, Mckenna R, Rollo M. Food Addiction, Binge Eating Disorder, and Obesity: Is There a Relationship?. Behav Sci (Basel). 2017;7(3) doi:10.3390/bs7030054

Brownley KA, Berkman ND, Peat CM, et al. Binge-Eating Disorder in Adults: A Systematic Review and Meta-analysis. Ann Intern Med. 2016;165(6):409-20. doi:10.7326/M15-2455

Guerdjikova AI, Mori N, Casuto LS, Mcelroy SL. Novel pharmacologic treatment in acute binge eating disorder - role of lisdexamfetamine. Neuropsychiatr Dis Treat. 2016;12:833-41. doi:10.2147/NDT.S80881

De jong M, Schoorl M, Hoek HW. Enhanced cognitive behavioural therapy for patients with eating disorders: a systematic review. Curr Opin Psychiatry. 2018;31(6):436-444. doi:10.1097/YCO.0000000000000452

Mcelroy SL, Hudson J, Ferreira-cornwell MC, Radewonuk J, Whitaker T, Gasior M. Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials. Neuropsychopharmacology. 2016;41(5):1251-60. doi:10.1038/npp.2015.275

Hudson JI, Mcelroy SL, Ferreira-cornwell MC, Radewonuk J, Gasior M. Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2017;74(9):903-910. doi:10.1001/jamapsychiatry.2017.1889

Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present–a pharmacological and clinical perspective. J Psychopharmacol (Oxford). 2013;27(6):479-96. doi:10.1177/0269881113482532

Coghill DR, Caballero B, Sorooshian S, Civil R. A systematic review of the safety of lisdexamfetamine dimesylate. CNS Drugs. 2014;28(6):497-511. doi: 10.1007/s40263-014-0166-2

Highlights of prescribing information: Vyvance. U.S. Food and Drug Administration.Binge eating disorder. National Eating Disorders Association.Heo Y, Duggan S.Lisdexamfetamine: A review in binge eating disorder.CNS Drugs. 2017;31(11):1015-1022. doi:10.1007/s40263-017-0477-1

Highlights of prescribing information: Vyvance. U.S. Food and Drug Administration.

Binge eating disorder. National Eating Disorders Association.

Heo Y, Duggan S.Lisdexamfetamine: A review in binge eating disorder.CNS Drugs. 2017;31(11):1015-1022. doi:10.1007/s40263-017-0477-1

Meet Our Review Board

Share Feedback

Was this page helpful?Thanks for your feedback!What is your feedback?HelpfulReport an ErrorOtherSubmit

Was this page helpful?

Thanks for your feedback!

What is your feedback?HelpfulReport an ErrorOtherSubmit

What is your feedback?

Vyvanse for Binge Eating Disorder#

A Word From Verywell#

Vyvanse for Binge Eating Disorder

A Word From Verywell